XGN - Exagen GAAP EPS revenue beats FY22 guidance raised
- Exagen press release ( NASDAQ: XGN ): Q3 GAAP EPS of -$0.47 beats by $0.29 .
- Revenue of $14.7M (+20.0% Y/Y) beats by $5.57M .
- For the full year 2022, the company is increasing its revenue guidance range to $40 million to $43 million. Consensus is $38.10M.
For further details see:
Exagen GAAP EPS, revenue beats, FY22 guidance raised